Related Experiment Video
Updated: Feb 22, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension
1School of Pharmacy, Shanghai University of Medicine & Health Sciences, 201318, Shanghai, China.
Herz
|September 19, 2017
Summary
The peroxisome proliferator-activated receptor γ2 (PPARγ2) Pro12Ala polymorphism’s Ala allele offers protection against hypertension. This meta-analysis confirms a significant association, highlighting its potential role in hypertension risk.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Disease Research
- Pharmacogenomics
Background:
- The peroxisome proliferator-activated receptor γ2 (PPARγ2) Pro12Ala polymorphism is linked to hypertension, but findings are inconsistent.
- Previous research suggests a potential association between PPARγ2 variants and cardiovascular health.
Purpose of the Study:
- To quantitatively assess the relationship between the PPARγ2 Pro12Ala polymorphism and hypertension risk.
- To clarify the conflicting results from previous studies through a comprehensive meta-analysis.
Main Methods:
- A meta-analysis was conducted, synthesizing data from 13 independent studies.
- Literature search performed across major databases including Scopus, Web of Science, PubMed, CNKI, and Wanfang.
- Statistical analysis included allelic, codominant, recessive, and dominant models to evaluate hypertension risk.
Main Results:
- The Ala allele of the PPARγ2 Pro12Ala polymorphism was significantly associated with reduced hypertension risk (OR = 0.723, 95% CI = 0.607-0.861).
- This association was consistent across various genetic models (codominant, recessive, dominant) and robust to sensitivity analyses.
- Exclusion of low-quality studies or those with confounding factors did not alter the observed protective effect.
Conclusions:
- The Ala allele of the PPARγ2 Pro12Ala polymorphism demonstrates a protective effect against hypertension.
- The genetic variant appears to function in a dominant manner, influencing hypertension susceptibility.
Keywords:
Genetic polymorphismHypertensionMeta-analysisPPAR gammaPeroxisome proliferator-activated receptorMore Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
30
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
01:29Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
24
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
01:27Pharmacogenetics of Drug Metabolism: Overview
31
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
31
01:27Principles of Pharmacogenetics: Types of Genetic Variants
29
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
29
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
47
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
47